
· Executive Brief
Appendix Cancer Awareness Month 2026
A practical executive framework for access, ownership, handoffs, measurement, and improvement.

Leadership signal
Appendix Cancer Awareness Month can serve as an executive operating checkpoint.
Awareness can generate questions and requests for help. Executive teams can prepare by clarifying the first point of contact, the qualified team that accepts the request, the handoff standard, and the method used to verify completion without assuming that one route fits every person.
Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.
Executive opening
Appendix cancer is found by accident, so the system has to be ready
Appendix cancer is rare, and it is often discovered by surprise. Many cases surface only when a pathologist examines an appendix removed for what looked like routine appendicitis. That makes the condition an unusual test of health-system reliability. The first surgeon rarely suspects it, and the team that can treat advanced disease may work in another city or region.
Recent cohorts show how quietly these tumors arrive. In a five-year review of 837 appendectomies at one tertiary surgical center, neoplasms were found in 1.1% of patients and none was suspected during the operation.[2] Another hospital found 43 neoplasms among 5,379 appendices removed for acute appendicitis, a cumulative incidence of 0.79%.[4] Small percentages across a high-volume operation still produce a steady flow of patients who need a deliberate next step.
For executives, the operational point is that the diagnosis begins after surgery, inside a pathology report. Whether that report reaches the surgeon, the patient and a specialized center on time depends on routing, ownership and follow-up rather than on one clinician’s memory. Leaders who treat the pathology report as the start of a cancer pathway, rather than the end of an emergency episode, can design for that reality. One specialized center identified timely referral as a key factor associated with improved survival.[6]
This brief adds research evidence to the executive guidance already on this page. It covers burden and measurement, the continuum from appendectomy to specialist care, access to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC), equity, the human infrastructure around patients and caregivers, and public communication. Figures cited here come from peer-reviewed studies and are reported with their settings. The aim is not to direct clinical care. It is to help leaders see where rare-tumor patients can be lost between services, and what evidence should shape the measures they review.
Current evidence
What current research says about burden, detection and outcomes
Incidence data for appendix cancer need careful reading. Using population-based registry data, one analysis found large increases in appendix cancer incidence between 2000–2009 and 2015-2020.[13] Incidence rose 17-fold in children aged 0–14 years, 6.5-fold in adolescents and young adults aged 15–39 years, and 2.5-fold in adults aged 40–49 years.[13] Neuroendocrine tumors accounted for 95%, 90% and 80% of that increase in the three age groups.[13] Among 3,446 adolescents and young adults with malignant appendix neuroendocrine tumors, 6-year cancer-specific survival was 99.4%.[13]
The same study showed how classification shapes headline trends. Colon carcinoma incidence in adolescents and young adults rose 61% with the appendix included and only 11% with the appendix excluded.[13] A German registry study analyzed the appendix separately from other colorectal sites and found that appendix cancer rates were rising for all age groups below 50 years.[12] Those increases tended to be higher for cancers with good prognosis, such as neuroendocrine neoplasms, small tumors and low-grade tumors.[12]
Detection before surgery remains limited. In a single-center study of 520 patients operated on for suspected appendicitis, 62 had appendiceal neoplasms, and the original CT report raised suspicion in only 22 of them, or 35.5%.[3] A combined clinical-radiomics model identified 32 of the 40 tumors that the original report had not flagged.[3] Overall, the combined model identified 53 of the 62 neoplasms, or 85.5%.[3] The authors noted that external validation is needed before clinical use.[3]
Some tumors are found only after an earlier operation. Among 1,615 patients treated with cytoreductive surgery and HIPEC for perforated appendiceal tumors at one center, 132 had high-grade appendiceal mucinous neoplasms, and 54 of those were diagnosed after a previous appendectomy.[1] Of the 20 patients in that group with no detectable disease on preoperative imaging, 7 had peritoneal disease confirmed in the surgical specimen.[1] Recurrence developed in 37 of the 132 patients during the study period, and all had peritoneal recurrence.[1] Normal imaging, in other words, did not close the question.
Outcome evidence is concentrated in specialized programs. One center that treated 160 patients with colorectal and appendiceal peritoneal metastases reported median overall survival of 25.1 months in its later cohort versus 13.8 months in its early cohort.[6] The authors linked this association to accumulated institutional experience and evolving treatment strategies.[6] For leaders, the evidence base is mostly retrospective and center-specific, which makes local outcome measurement essential rather than optional.
Figure 1
Appendiceal tumors are often unsuspected until pathology or later surgery
Percent of patients in each study cohort, as reported in the source abstract. Values are copied from the cited studies [1], [2], [3], [4]; none is estimated.
Data note. These values come from different studies, centers and denominators, so this is an indirect comparison; only the two bars from the same cohort can be read side by side.
Limitation. All values are from single-center retrospective cohorts and reflect each center’s referral pattern and pathology practice.
Figure data (5 rows)
| Measure | Value | Population, setting and year as reported | Source |
|---|---|---|---|
| Appendiceal neoplasms among appendectomies for acute appendicitis | 0.79% | 43 of 5,379 appendices, one hospital, 2017 to 2023 | [4] |
| Appendiceal neoplasms among appendectomies, tertiary surgical center | 1.1% | 837 appendectomies over five years; all neoplasms unsuspected intraoperatively | [2] |
| Neoplasms suspected in the original CT report | 35.5% | 22 of 62 pathologically confirmed neoplasms, single center, patients operated on for suspected appendicitis | [3] |
| Peritoneal disease found despite normal preoperative imaging | 35% | 7 of 20 patients with a high-grade mucinous neoplasm at earlier appendectomy, single center, 2015 to 2023 | [1] |
| High-grade mucinous neoplasms diagnosed after a previous appendectomy | 40.9% | 54 of 132 patients (40.9%) treated with cytoreductive surgery and HIPEC at the same center | [1] |

Continuum of care
Where the appendix cancer pathway breaks between settings
The appendix cancer continuum often starts in an emergency department and an operating room that are not organized for cancer care. A patient is treated for appendicitis, discharged and considered recovered. Days later, a pathology report changes the diagnosis. In one surgical cohort, appendiceal neoplasms were uniformly unsuspected during the operation.[2] The first handoff, from pathology back to the operating surgeon and then to the patient, is therefore the most fragile point in the route. In practice, that handoff often crosses from an acute care team to an outpatient clinic that has never met the patient.
A second break point appears when appendicitis is managed without surgery. A recent review reported that recurrence after successful nonoperative management is commonly 12–24% and concentrated in the first 6 months.[5] In adults with a periappendiceal abscess, tumor prevalence reached approximately 5–10% in patients aged 35–39 years and 14–20% in cohorts aged 40 years or older.[5] The review described structured imaging follow-up for selected younger patients and shared decision-making about interval surgery.[5] Each of those follow-up steps needs an owner and a scheduled date.
The third break point is the transfer to a specialized center. Pathology classification matters at that stage. In a peritoneal tumor center cohort of 210 patients with appendiceal goblet cell adenocarcinoma, cases were re-reviewed for histological and two-tiered grading.[9] The two-tiered grading showed improved risk stratification compared with earlier systems.[9] For referring hospitals, that implies slides, reports and imaging must travel with the patient, and second review should be expected rather than resisted.
The final break point comes after discharge from complex surgery. At one high-volume center, thromboembolic events occurred in 63 of 554 patients after cytoreductive surgery and HIPEC for pseudomyxoma peritonei.[11] Median time to diagnosis was 8 days for pulmonary embolism and 11 days for deep vein thrombosis.[11] The authors described these events as frequent and under-reported.[11] Some complications may surface after a patient has returned home, often far from the operating team.
Long-term follow-up is the least studied link. A systematic review screened 263 studies and found only five that reported dietary or nutrition outcomes for adults with pseudomyxoma peritonei or appendix cancer beyond the postoperative period.[14] No included study assessed food or nutrient intakes.[14] The continuum, in practice, often ends at discharge from the surgical service.
Figure 3
Why the pathway breaks
People
- Few clinicians see enough cases to recognize the pattern
- Caregivers carry high stress and burden without named support
- Limited dietitian and survivorship roles after complex surgery
Process
- No owner for an unexpected pathology result after discharge
- Surveillance after nonoperative appendicitis care not scheduled by default
- Slides and imaging not sent with referrals for expert review
Technology
- Routine CT reports miss many tumors before surgery
- Detection models not yet externally validated
- Pathology results not routed to a tracked work queue
Environment
- Specialized centers concentrated in a few locations
- Long travel for patients and caregivers
- Complications surfacing after patients return home
Policy
- No formal referral agreement with a specialized center
- Financial toxicity not screened or addressed
- Second pathology review not routinely supported
Measurement
- Appendix tumors combined with colorectal cancer in reports
- Post-discharge complications under-reported
- Patient-reported regret and burden not collected
Unranked qualitative cause-and-effect diagram for the outcome in the box: Patients with an unexpected appendiceal tumor are lost or delayed between appendectomy, specialist review, complex surgery and long-term follow-up Causes are assembled from the cited literature [2], [3], [5], [9], [10], [11], [12], [14]; categories are not weighted and their order carries no meaning.
Data note. Qualitative; no frequencies are implied.
Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.
Figure data (6 rows)
| Category | Causes drawn from the cited literature |
|---|---|
| People | Few clinicians see enough cases to recognize the pattern; Caregivers carry high stress and burden without named support; Limited dietitian and survivorship roles after complex surgery |
| Process | No owner for an unexpected pathology result after discharge; Surveillance after nonoperative appendicitis care not scheduled by default; Slides and imaging not sent with referrals for expert review |
| Technology | Routine CT reports miss many tumors before surgery; Detection models not yet externally validated; Pathology results not routed to a tracked work queue |
| Environment | Specialized centers concentrated in a few locations; Long travel for patients and caregivers; Complications surfacing after patients return home |
| Policy | No formal referral agreement with a specialized center; Financial toxicity not screened or addressed; Second pathology review not routinely supported |
| Measurement | Appendix tumors combined with colorectal cancer in reports; Post-discharge complications under-reported; Patient-reported regret and burden not collected |
Access
Making specialized surgery and expert review reachable
Access to appendix cancer care is largely access to a small number of experienced teams. Cytoreductive surgery with HIPEC is technically complex and resource intensive. A Brazilian cancer center described it as a modality associated with significant surgical morbidity and resource demands.[8] That center achieved complete cytoreduction in 133 of 139 patients, or 95.6%, and reported 10-year overall survival of 64.8%.[8] The authors tied those results to performance at experienced referral centers and specialized multidisciplinary care.[8]
National data show how treatment choices differ across the population that reaches surgery. In a national registry cohort, 888 patients had non-mucinous appendiceal cancer with peritoneal metastases and were treated from 2018 to 2022.[7] Three-year overall survival was 58.4% for HIPEC without additional systemic therapy and 20.2% for no chemotherapy.[7] Compared with surgery alone, HIPEC-based therapy was associated with a hazard ratio for death of 0.57.[7] These are observational comparisons among selected patients, not proof that one route suits everyone.
Experience accumulates over time, which makes referral volume an access issue. At one center, 5-year overall survival was 25.9% in the later cohort and 11.9% in the early cohort.[6] Achieving complete cytoreduction and timely referral to a specialized center were identified as key factors associated with improved survival.[6] Health systems that perform few of these operations should weigh whether a formal referral partnership would serve patients better than occasional local cases. The same question applies to pathology review, anesthesia support and the intensive care capacity that complex surgery requires.
Access also includes reaching an accurate diagnosis early. A clinical-radiomics model flagged 76 of 520 patients, or 14.6%, as model-positive, including 23 false-positive cases.[3] Each additional tumor identified beyond the original CT report corresponded to roughly 2 to 3 model-positive cases.[3] Executives considering such tools should plan for the extra review workload, not only the detection gain.
Selection for complex surgery is itself a specialist judgment. In the goblet cell adenocarcinoma cohort, cytoreductive surgery was carried out in 135 of 210 patients, or 64%, and systemic chemotherapy was given to 85 patients.[9] Patients were selected for surgery based on disease distribution and burden.[9] That is why access to specialist assessment matters as much as access to the operation itself.
Executive guidance · System route
Build one visible operating route for Appendix Cancer Awareness Month.
Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.
The route at a glance
- Listen
- Clarify entry
- Navigate across services
- Protect transitions
- Verify and learn
Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.
Listen
Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.
Clarify entry
Publish a plain-language first step and identify who receives requests through each approved channel.
Navigate across services
Make the receiving service, required information, current status, and next accountable owner visible whenever the route crosses an organizational boundary.
Protect transitions
Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations.
Verify and learn
Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.
Figure 2
The system route as one flow
The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.
Data note. Shows sequence and handoffs only; it carries no counts or rates.
Limitation. Local processes may add, merge or reorder stages under organizational policy.
Figure data (5 rows)
| Stage | What the stage requires |
|---|---|
| Listen | Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions. |
| Clarify entry | Publish a plain-language first step and identify who receives requests through each approved channel. |
| Navigate across services | Make the receiving service, required information, current status, and next accountable owner visible whenever the route crosses an organizational boundary. |
| Protect transitions | Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations. |
| Verify and learn | Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals. |
Equity and trust
Who reaches expert care and who carries the cost
Rare-tumor care concentrates expertise, and concentration moves the burden of access onto patients and families. In a survey of caregivers of patients with appendix cancer who underwent cytoreductive surgery and HIPEC, higher financial toxicity was seen among patients and caregivers who traveled 50 miles or more to the treatment center.[10] Distance, in other words, is not only a scheduling detail. It is an equity measure that leaders can track.
Income also appears in patient-reported outcomes. In a survey of 122 patients distributed through a patient research foundation, 85.2% reported no regret about undergoing the procedure and 14.8% expressed regret.[15] Patients with higher regret more often had income at or below $74,062 (72.2% versus 44.2%).[15] They also more often had hospital stays longer than 30 days (38.9% versus 4.8%) and a new ostomy (27.8% versus 7.7%).[15]
These findings point to equity risks that standard quality reports may miss. A patient with fewer resources may face long travel, extended stays away from home and complications without a local team that knows the history. The authors suggested targeted perioperative psychological support and symptom management.[15] Health systems can treat regret, financial toxicity and travel distance as measurable signals rather than private experiences. Patients who underwent more than one procedure also reported regret more often (56.3% versus 12.6%).[15] A health system that does not collect these signals cannot see who is struggling.
Equity also depends on whether data are classified fairly. Registry analyses show that the inclusion of appendix tumors changed the apparent growth of colon carcinoma in young adults from 11% to 61%.[13] A German study chose to examine the appendix separately for that reason.[12] Equity dashboards that combine appendix and colorectal cancer may misread which communities are affected and where screening or referral gaps truly sit. Reports that show appendix tumors as their own category help leaders target outreach accurately.
Trust is built when patients understand why they are being sent elsewhere and what will happen next. One surgical review described shared decision-making as central to decisions about interval surgery after nonoperative appendicitis care.[5] Clear explanations of risk, referral and follow-up help patients and families accept a route that may involve travel and repeated testing.

Human infrastructure
The people who carry patients and families through rare-tumor care
Appendix cancer care relies on a small, specialized workforce: pathologists who recognize unusual histology, radiologists who notice subtle findings, surgeons trained in cytoreduction and nurses who coordinate long recoveries. Each group sees a few cases at a time, so knowledge must be shared deliberately. A single-center study found that the original CT report raised suspicion in 35.5% of confirmed neoplasms, a reminder of how hard these tumors are to see.[3] Low volume makes formal case conferences and shared protocols more important, not less.
Caregivers form part of that infrastructure, even though they are not on the payroll. In a survey of 34 caregivers, 58.8% reported feeling stressed caring for their family member and 26.5% felt they had lost control of their life since the illness.[10] Caregiver burden was significantly related to increased decision regret.[10] Half of caregivers reported high burden, which was associated with worse quality of life and regret.[10]
Nurse navigation and survivorship services are the natural places to absorb that load. The caregiver study authors called for future work on support and resources for caregivers, both perioperatively and in the long term.[10] A systematic review similarly found that nutrition after surgery for pseudomyxoma peritonei and appendix cancer is poorly reported.[14] It called for validated dietary assessment tools to improve posttreatment care.[14] Dietitians, navigators and survivorship nurses can fill those gaps if their roles are funded and named.
The specialist team itself needs protected learning time and stable volume. At one specialized center, the later cohort’s survival gains were associated with accumulated institutional experience and changes in treatment strategy.[6] At another, the two-tiered pathology grading came from re-reviewing archived cases.[9] Both depend on people with time to review cases, audit results and teach referring colleagues.
Clinical teams also need shared knowledge to recognize risk across services. One review reported that interval CT or MRI findings, including dilated or cystic morphology, mural abnormalities, calcification, mucin or a base mass, identify higher-risk patients.[5] Radiologists, surgeons and advanced practice clinicians who share one follow-up standard are less likely to let those findings sit unread. Education for emergency and general surgery teams can be brief, but it has to reach every site that performs appendectomies.
Executive guidance · Operating dashboard
Use a small dashboard to expose friction and ownership.
Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.
Four operating signals
Each signal pairs an executive question with one candidate local measure, set out below.
Executive guidance · Signal
Entry-point clarity
Can people and staff identify the approved first step without searching across conflicting instructions?
- Candidate local measure
- Locally defined contact, routing, and repeat-contact signals by channel and service.
Executive guidance · Signal
Ownership reliability
Does a specific team accept each request and make its status visible?
- Candidate local measure
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
Executive guidance · Signal
Navigation continuity
Where does ownership become unclear as people move among information, evaluation, services, and follow-through?
- Candidate local measure
- Locally defined unaccepted handoffs, repeated contacts, missing information, unresolved routes, and navigation feedback.
Executive guidance · Signal
Improvement closure
Does the organization correct recurring friction and report what changed?
- Candidate local measure
- Selected barriers, assigned actions, completion status, and post-change review.
Figure 4
The operating system behind the dashboard
The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.
Data note. Structural diagram; no measured values.
Limitation. Owners are candidates to be confirmed locally.
Figure data (4 rows)
| Operating signal | Candidate owner |
|---|---|
| Entry-point clarity | Executive sponsor and operational lead |
| Ownership reliability | Operational owner and participating teams |
| Navigation continuity | Sending and receiving owners |
| Improvement closure | Improvement owner and executive sponsor |
Executive guidance · Handoff workflow
Close the loop across teams, settings, and partners.
A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.
How responsibility moves
Lane A
From message to accepted ownership
- Confirm the approved message and intended audience.
- Publish the actual entry point and receiving role.
- Acknowledge receipt using the locally approved method.
- Escalate when ownership or response remains unclear.
Lane B
From accepted ownership to verified follow-through
- Record the next accountable owner and visible status.
- Name the receiving service and confirm acceptance without promising a clinical determination or outcome.
- Keep unresolved work visible across boundaries.
- Confirm closure or document the continuing exception.
Executive guidance · Executive scorecard
Give leaders one view of route reliability and improvement.
The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.
Who reviews what
- Executive sponsor and operational lead
- Operational owner and participating teams
- Sending and receiving owners
- Improvement owner and executive sponsor
Candidate owners named in the scorecard, confirmed locally.
| Operating signal | Executive question | Candidate owner | Suggested review point |
|---|---|---|---|
| Entry-point clarity | Can people and staff identify the approved first step without searching across conflicting instructions? | Executive sponsor and operational lead | At campaign launch and close |
| Ownership reliability | Does a specific team accept each request and make its status visible? | Operational owner and participating teams | At a locally defined cadence |
| Navigation continuity | Where does ownership become unclear as people move among information, evaluation, services, and follow-through? | Sending and receiving owners | At a locally defined cadence |
| Improvement closure | Does the organization correct recurring friction and report what changed? | Improvement owner and executive sponsor | Until action is verified |
Figure 5
Control points for the incidental appendiceal tumor pathway
| Control point | Risk if missing | Owner | Evidence of control |
|---|---|---|---|
| Unexpected neoplasm on appendectomy pathology routed to a tracked queue | Result reaches no one after the patient is discharged | Chief medical officer with pathology and surgery chairs | Share of incidental results acknowledged and communicated within a locally defined window |
| Scheduled follow-up after nonoperative appendicitis care | Age-linked tumor risk missed when imaging or interval surgery is not arranged | Surgical service line leader | Share of eligible patients with a booked follow-up before discharge |
| Referral agreement with a specialized peritoneal malignancy center | Delayed or ad hoc transfer for complex surgery | Chief operating officer and cancer program director | Signed agreement and tracked time from pathology report to first specialist visit |
| Slides, reports and imaging sent for expert re-review | Inaccurate grading shapes treatment and surveillance | Pathology department leader | Share of referred cases with materials received before the specialist visit |
| Post-discharge complication monitoring and return route | Late complications treated far from the team that knows the history | Specialized center nursing leader with referring hospital | Documented contact plan and complication capture after discharge |
| Caregiver burden and financial toxicity screening | Families absorb hidden travel and cost burdens | Navigation and social work leaders | Screening rate and resources offered to families traveling long distances |
| Registry reports that separate appendix from colorectal sites | Trend and equity data misread | Cancer registry and quality analytics lead | Appendix reported as its own category in board dashboards |
Control points derived from the cited evidence [1], [3], [5], [6], [9], [10], [11], [12], [13] and this brief’s executive guidance.
Data note. Each row is a control to verify, not a measured result.
Limitation. Owners and evidence of control must follow local policy and applicable requirements.
Public communication
Explaining a rare, confusing diagnosis clearly and honestly
Public messages about appendix cancer must handle two truths at once. Some appendix tumors carry an excellent prognosis, while others spread through the abdomen and require major surgery. Registry data showed 6-year cancer-specific survival of 99.4% for young people with malignant appendix neuroendocrine tumors.[13] The authors argued that these tumors should not be counted with colorectal cancer in trend analyses.[13] Communication that blurs these groups can alarm some patients and falsely reassure others.
Awareness campaigns should also avoid suggesting that symptoms reliably point to a tumor. In one cohort, appendiceal neoplasms presented as clinically uncomplicated appendicitis.[2] In another, the original CT report raised suspicion of a neoplasm in 22 of 62 cases.[3] The more useful public message is about follow-through: patients should receive their pathology results, understand them and know who will contact them next. Hospitals can also explain how a second review of pathology works and why it is routine at specialized centers.
Communication with referring clinicians matters as much as public outreach. Among patients with a high-grade mucinous neoplasm found at earlier appendectomy, 37% had no detectable disease on preoperative imaging.[1] Yet 35% of those patients had histologically confirmed peritoneal disease at cytoreductive surgery.[1] Referring teams need clear guidance on when to call a specialized center, even when imaging looks normal. A short referral checklist, a named contact at the receiving center and a promised response time make that guidance usable on a busy service.
Finally, leaders can share outcome and safety data openly. One high-volume center reported thromboembolic events in 11.4% of patients with pseudomyxoma peritonei after surgery, including pulmonary embolism in 7.4% and deep vein thrombosis in 4.0%.[11] A national cohort reported 3-year overall survival ranging from 20.2% to 58.4% across treatment groups.[7] Publishing local results with the same candor builds trust with patients, referring physicians and boards.
Messages to caregivers deserve their own plan. In the caregiver survey, the most common burdens were feeling stressed and feeling a loss of control since the illness began.[10] Plain-language materials on travel, lodging, recovery timelines and whom to call after discharge can address those concerns directly. Leaders can test these materials with families who have completed treatment and revise them each year.

Executive guidance · 90-day plan
Turn the observance into one sustained operating change.
The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.
Ninety days, three moves
- Days 1–30See the current route
- Days 31–60Build the reliable path
- Days 61–90Make the change visible
Days 1–30 · Listen and map
See the current route
- Name an executive sponsor and an operational owner.
- Listen to people using the route and representative frontline teams.
- Map how Appendix Cancer Awareness Month communications connect to real entry points, owners, transitions, and escalation.
- Select one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and test
Build the reliable path
- Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
- Validate the design with every sending and receiving team involved.
- Test one cross-service navigation handoff and correct the point where status or ownership becomes unclear.
- Test the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verify
Make the change visible
- Launch the redesigned route with a small set of locally defined measures.
- Review unresolved work and recurring friction using a learning approach.
- Correct implementation barriers and record who owns each remaining dependency.
- Report what changed, what evidence was reviewed, and what still requires live oversight.
Figure 6
The 90-day plan on one timeline
The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.
Data note. Time boxes are a management framework, not a clinical timeline.
Limitation. Durations are uniform 30-day windows; real tasks may span windows.
Figure data (12 rows)
| Window | Action |
|---|---|
| Days 1–30 · Listen and map | Name an executive sponsor and an operational owner. |
| Days 1–30 · Listen and map | Listen to people using the route and representative frontline teams. |
| Days 1–30 · Listen and map | Map how Appendix Cancer Awareness Month communications connect to real entry points, owners, transitions, and escalation. |
| Days 1–30 · Listen and map | Select one recurring barrier that the organization can responsibly address. |
| Days 31–60 · Design and test | Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal. |
| Days 31–60 · Design and test | Validate the design with every sending and receiving team involved. |
| Days 31–60 · Design and test | Test one cross-service navigation handoff and correct the point where status or ownership becomes unclear. |
| Days 31–60 · Design and test | Test the route in more than one representative setting or operating period where practical. |
| Days 61–90 · Implement and verify | Launch the redesigned route with a small set of locally defined measures. |
| Days 61–90 · Implement and verify | Review unresolved work and recurring friction using a learning approach. |
| Days 61–90 · Implement and verify | Correct implementation barriers and record who owns each remaining dependency. |
| Days 61–90 · Implement and verify | Report what changed, what evidence was reviewed, and what still requires live oversight. |
Executive guidance · Leadership close
Make Appendix Cancer Awareness Month a starting point, not an endpoint.
Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.
Leadership commitment
Make ownership visible, test the route, and report what improved.
Executive action kit · Month observance
Turn Appendix Cancer Awareness Month into accountable action.
A practical executive framework for access, ownership, handoffs, measurement, and improvement.
Leadership focus
Use this observance to examine navigation, longitudinal ownership, and specialty-care coordination. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.
Workforce lens
Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the information, diagnostic navigation, support, and follow-through pathway.
Patient and community lens
Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.
Equity and access lens
Review whether language, transportation, cost, digital access, disability, geography, or trust changes a person’s ability to complete the locally approved route.
Five-minute briefing
Inspect the operating sequence
Listen with people using the pathway, caregivers, navigation teams, clinical services, and community partners. Find one a confusing entry point, unowned transition, or unresolved navigation need, then test the locally approved route from entry through acknowledged follow-through.
- Listen
- Clarify entry
- Navigate across services
- Protect transitions
- Verify and learn
Leadership actions for this week
- Name an executive sponsor and frontline operating owner.
- Ask people using and operating the pathway where ownership becomes unclear.
- Test one representative route from first question to acknowledged next step.
- Select one barrier that can be corrected without overstating the evidence.
- Set a review date and define how completion will be verified.
Candidate measures
Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.
- Locally defined contact, routing, and repeat-contact signals by channel and service.
- Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
- Locally defined unaccepted handoffs, repeated contacts, missing information, unresolved routes, and navigation feedback.
Department readiness checklist
- The public and staff entry points match the actual approved process.
- A specific role accepts each request, referral, or escalation.
- Handoffs include acknowledgment and a visible unresolved state.
- Language, disability, digital, transportation, and trust barriers receive explicit review.
- Communications do not introduce unsupported themes, statistics, or clinical advice.
- A named leader will review what changed after the observance.
Intended audiences
- Executive and Operational Leaders
- Patient Experience and Access Leaders
Staff communication template
During Appendix Cancer Awareness Month, our organization will connect awareness with a practical review of the information, diagnostic navigation, support, and follow-through pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.
Community communication template
Appendix Cancer Awareness Month is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.
Measurement worksheet
- Signal
- What observable condition will show whether the route works?
- Definition
- What is included, excluded, and counted?
- Owner
- Who reviews the signal and acts on exceptions?
- Cadence
- When will leaders review it?
- Equity check
- Which differences require protected, locally appropriate review?
- Closure
- What evidence will confirm the improvement was completed?
- Editorial review
- Completed
- Source records
- 2 listed under Authoritative resources
- Review standard
- Sourced facts remain separated from original executive guidance
- Clinical boundary
- No new statistical or clinical claim was added by this action kit
Sources and content boundary
Authoritative resources
Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.
Peer-reviewed references
References
Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .
- 1.Flood MP, Warner NR, Samuel VM, Lee GH, Tzivanakis A, Dayal S, et al. Clinicopathological features and outcomes in 132 patients with perforated high grade appendiceal mucinous neoplasm treated with cytoreductive surgery and HIPEC - A single institution experience. European Journal of Surgical Oncology. 2026;52(10):112046. https://doi.org/10.1016/j.ejso.2026.112046
- 2.Trifunović N, Mitrović N, Trifunović J, Nikolić M, Filipović S. Immune-Inflammatory Markers Associated With Occult Appendiceal Neoplasms in Patients With Acute Appendicitis. The American Surgeon. 2026;92(10):2713-2719. https://doi.org/10.1177/00031348261441671
- 3.Zhang W, Guan Z, Mao J, Qi H, Li W, Yu S, et al. CT-based clinical-radiomics model for preoperative identification of appendiceal neoplasms in patients undergoing surgery for suspected appendicitis. Asian Journal of Surgery. 2026. https://doi.org/10.1016/j.asjsur.2026.08.170
- 4.Roa-Cáceres C, Barillas-Otero N, Vera-Portilla R, Roa-Cáceres M, Olivares-Villalón S, Bezares-Gallardo K. Neoplasias apendiculares incidentales: Hallazgos histopatológicos en apendicitis aguda. Revista de Cirugia. 2026;78(5):464-469. https://doi.org/10.35687/s2452-454920260053068
- 5.Gosavi R, McMurrick P, Teoh W, Ooi G, Narasimhan V. Interval Appendicectomy after Conservative Management of Complicated Appendicitis: Balancing Recurrence, Neoplasm Risk, and Surveillance Strategies. Digestive Surgery. 2026;43(3):146-150. https://doi.org/10.1159/000552093
- 6.Suh JW, Kang H, Namgung H, Jo JW, Lee SC, Park DG. Impact of Accumulated Institutional Experience on Outcomes of Cytoreductive Surgery with Intraperitoneal Chemotherapy for Colorectal and Appendiceal Peritoneal Metastases: Early Versus Later Cohort Analysis. Cancers. 2026;18(9):1416. https://doi.org/10.3390/cancers18091416
- 7.Brar G, Castillo D, Lwin T, Raoof M, Kasi P, Fakih M, et al. The Role of Systemic Chemotherapy to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients With Appendiceal Cancers. Clinical Colorectal Cancer. 2026;25(2):209-215. https://doi.org/10.1016/j.clcc.2026.01.001
- 8.Marques TMDM, Lourenco SR, Kupper BEC, Bezerra ALR, Stevanato PR, Bezerra TS, et al. Long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal neoplasms: A Brazilian cancer center experience. Surgery. 2026;200. https://doi.org/10.1016/j.surg.2026.110562
- 9.Strach MC, Aziz O, Nonaka D, Nagaraju RT, Clouston H, Mullamitha S, et al. Long-term outcomes, pathological classification and prognostic factors in localised and advanced appendiceal goblet cell adenocarcinoma following cytoreductive surgery, intraperitoneal and systemic chemotherapy. ESMO Open. 2026;11(7):108245. https://doi.org/10.1016/j.esmoop.2026.108245
- 10.Greenbaum A, Kosich M, Marek L, Ward E, Pankratz S, Mishra SI, et al. Decision Regret and Burden in Caregivers of Patients with Appendiceal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology. 2026;33(2):1684-1693. https://doi.org/10.1245/s10434-025-18399-y
- 11.Brindl N, Chandrakumaran K, Shah N, Mohamed F, Cecil T, Moran B, et al. Deep vein thrombosis and pulmonary embolism following cytoreductive surgery and HIPEC for PMP of appendiceal origin. European Journal of Surgical Oncology. 2026;52(10):112043. https://doi.org/10.1016/j.ejso.2026.112043
- 12.Voigtländer S, Kajüter H, Wellmann I, Szentkirályi A, Holleczek B, Arndt V, et al. Incidence Trends of Early-Onset Colorectal Cancer in Germany: A Registry-Based Study From 2003 to 2023. International Journal of Cancer. 2026;159(9):2207-2218. https://doi.org/10.1002/ijc.70600
- 13.Bleyer A, Ries LAG, Cameron DB, Mansfield SA, Siegel SE, Barr RD. Colon, colorectal, and all cancer incidence increase in the young due to appendix reclassification. Journal of the National Cancer Institute. 2025;117(7):1340-1349. https://doi.org/10.1093/jnci/djaf038
- 14.Skinner JA, Whatnall M, Leary M, Carey S, Steffens D, Burrows TL. What Are the Dietary Intakes and Nutritional Outcomes of Adults With Pseudomyxoma Peritonei/Appendix Cancer Beyond the Postoperative Period: A Systematic Review. Journal of Human Nutrition & Dietetics. 2025;38(6):1-13. https://doi.org/10.1111/jhn.70145
- 15.Graves A, Sadjadi J, Kosich M, Ward E, Sood D, Fahy B, et al. Decision Regret in Patients with Appendiceal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology. 2024;31(12):7978-7986. https://doi.org/10.1245/s10434-024-16013-1
Claim-to-source matrix
What each source supports
Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.
| Claim group | Sources | Years | Used in | Limitation |
|---|---|---|---|---|
| Incidence trends and the effect of reclassifying appendix tumors | [13] [12] | 2026, 2025 | Current evidence | Registry analyses depend on coding and classification changes; trends may reflect detection and coding as well as true disease change. |
| Incidental appendiceal neoplasms found after appendectomy | [2] [4] [1] | 2026 | Executive opening | Single-center retrospective cohorts with different case mixes and pathology practices. |
| Preoperative CT detection and clinical-radiomics models | [3] | 2026 | Access | Single-center retrospective model development with internal validation only; external validation is needed. |
| Nonoperative management, recurrence and age-linked neoplasm risk | [5] | 2026 | Continuum of care | Narrative review summarizing heterogeneous cohorts; ranges are approximate. |
| Specialized center outcomes, referral timing and experience | [6] [8] | 2026 | Access | Single-center retrospective cohorts; temporal and selection effects cannot be separated from experience. |
| Treatment groups in national registry data | [7] | 2026 | Access | Observational registry analysis among selected patients; residual confounding likely. |
| Pathology re-review and grading for goblet cell adenocarcinoma | [9] | 2026 | Continuum of care | Single peritoneal tumor center over a long period with evolving practice. |
| Complications after discharge from cytoreductive surgery and HIPEC | [11] | 2026 | Continuum of care | Single high-volume center; routine screening practice may differ elsewhere. |
| Caregiver burden, financial toxicity and travel distance | [10] | 2026 | Human infrastructure | Small anonymous survey of 34 caregivers; self-selection likely. |
| Decision regret, income and patient-reported outcomes | [15] | 2024 | Equity and trust | Foundation-distributed survey; respondents may not represent all patients. |
| Nutrition and long-term follow-up evidence | [14] | 2025 | Human infrastructure | Systematic review of only five small studies with heterogeneous designs. |

About the author
Greg Wahlstrom
MBAHCM
President and Chief Executive Officer, The Healthcare Executive
View Greg’s profile©2014 – 2026 The Healthcare Executive. All rights reserved.

